EXHIBIT 34

	Page 1
1	UNITED STATES DISTRICT COURT
2	NORTHERN DISTRICT OF OHIO
3	EASTERN DIVISION
4	
5	~~~~~~~~~~~~~~~~
6	
7	IN RE: NATIONAL PRESCRIPTION MDL No. 2804
	OPIATE LITIGATION
8	Case No.
	17-md-2804
9	_
	Judge Dan Aaron
10	Polster
11	This document relates to:
12	The County of Summit, Ohio, et al. v. Purdue
13	Pharma L.P., et al.
13	Case No. 18-OP-45090 (N.D. Ohio)
14	Cabe No. 10 01 45050 (N.D. 01110)
15	
	~~~~~~~~~~~~~~~~~
16	
	Videotaped Deposition of
17	
	KENNETH R. BALL II
18	
	November 7, 2018
19	9:04 a.m.
20	
21	_ ,
0.0	Taken at:
22	Hilton Condon Inn
23	Hilton Garden Inn 1307 East Market Street
∠ 3	Akron, Ohio
24	ARIOII, OIIIO
25	Stephen J. DeBacco, RPR
_ ~	

Veritext Legal Solutions
www.veritext.com
888-391-3376

```
Page 2
1
    APPEARANCES:
           On behalf of the City of Akron, Summit
           County, and the Witness:
3
                 Motley Rice LLC, by
4
                 JAMES W. LEDLIE, ESQ.
                 CAROLINE RION, ESQ.
5
                 28 Bridgeside Boulevard
                 Mt. Pleasant, South Carolina 29464
6
                 (843) 216-9252
7
                 jledlie@motleyrice.com
                 (843) 216-9168
                 crion@motleyrice.com
8
9
           On behalf of McKesson Corporation:
10
                 Covington & Burling, by
11
                 JENNIFER SAULINO, ESQ.
                 One CityCenter
                 850 Tenth Street Northwest
12
                 Washington, D.C. 20001-4956
13
                 (202) 662-5305
                 isaulino@cov.com
14
                 -and-
15
                 Covington & Burling, by
16
                 STEPHEN F. RAIOLA, ESQ.
                 One CityCenter
                 850 Tenth Street Northwest
17
                 Washington D.C., 20001-4956
18
                 202-662-5786
                 sraiola@cov.com
19
20
21
22
23
24
25
```

```
Page 3
     APPEARANCES, Continued:
1
           On behalf of Johnson & Johnson and
2
           Janssen Pharmaceuticals, Inc.:
3
                 Tucker Ellis, LLP, by
                 BRENDA A. SWEET, ESQ.
4
                 950 North Main Avenue, Suite 1100
5
                 Cleveland, Ohio 44113
                 (216) 696-2493
                 brenda.sweet@tuckerellis.com
6
           On behalf of Endo Health Solutions, Inc.,
           and Endo Pharmaceuticals, Inc., via
8
           Teleconference:
9
                 Baker Hostetler, by
                 TERA N. COLEMAN, ESQ.
10
                 Key Tower
11
                 127 Public Square, Suite 2000
                 Cleveland, Ohio 44114-1214
12
                 (216) 861-7582
                 tcoleman@bakerlaw.com
13
           On behalf of Prescription Supply, Inc.:
14
                 Pelini, Campbell & Williams, by
15
                 KRISTEN E. CAMPBELL TRAUB, ESQ.
                 Bretton Commons, Suite 400
16
                 8040 Cleveland Avenue Northwest
17
                 North Canton, Ohio 44720
                 (330) 305-6400
                 kec@pelini-law.com
18
19
           On behalf of Walmart, Inc.:
20
                 Jones Day, by
21
                 LISA B. GATES, ESO.
                 901 Lakeside Avenue
                 Cleveland, Ohio 44114-1190
22
                  (212) 586-7154
2.3
                 lgates@jonesday.com
24
25
```

```
Page 4
    APPEARANCES, Continued:
1
           On behalf of Walgreens:
2
3
                 Bartlit Beck LLP, by
                 MATTHEW BREWER, ESQ.
                 54 West Hubbard Street
4
                 Chicago, Illinois 60654
                 (312) 494-4432
5
                 batthew.brewer@bartlitbeck.com
6
           On behalf of Allergan Finance, LLC, via
           Veritext Virtual:
8
                 Kirkland & Ellis LLP, by
9
                 TUCKER HUNTER, ESO.
                 300 North LaSalle
10
                 Chicago, Illinois 60654
                 (312) 862-3758
                 tucker.hunter@kirkland.com
11
12
           On behalf of Cardinal Health, Inc.:
1.3
                 Williams & Connolly LLP, by
14
                 MIRANDA PETERSEN, ESO.
                 725 12th Street Northwest
15
                 Washington, D.C. 20005
                 (202) 434-5686
16
                 mpetersen@wc.com
17
           On behalf Endo Health Solutions, Inc.,
           and Endo Pharmaceuticals, Inc.:
18
19
                 Arnold & Porter, by
                 JOHN D. LOMBARDO, ESQ.
20
                 777 South Figueroa Street
                 44th Floor
21
                 Los Angeles, California 90017-5844
                 john.lombardo@arnoldporter.com
22
23
24
25
```

```
Page 5
    APPEARANCES, Continued:
1
 2
           On behalf of AmerisourceBergen, via
           Teleconference:
 3
 4
                 Reed Smith, LLP, by
                 NICHOLAS R. RODRIGUEZ, ESQ.
5
                 Three Logan Square
                  1717 Arch Street, Suite 3100
                 Philadelphia, Pennsylvania 19103
6
                  (215) 241 7947
7
                 nrodriguez@reedsmith.com
8
9
10
    ALSO PRESENT:
11
                 Richard Hand, Morgan, Lewis &
                 Bockius, via Teleconference
12
                 Shaun Crum, Legal Videographer
13
14
15
16
17
18
19
20
21
22
2.3
24
25
```

	Page 6
1	TRANSCRIPT INDEX
2	
3	APPEARANCES
4	
5	INDEX OF EXHIBITS
6	
7	EXAMINATION OF KENNETH R. BALL II
8	By Ms. Saulino
9	By Mr. Lombardo 331
10	By Mr. Ledlie: 368
11	By Ms. Saulino 375
12	
13	REPORTER'S CERTIFICATE
14	
15	EXHIBIT CUSTODY
16	EXHIBITS RETAINED BY THE COURT REPORTER
17	
18	
19	
2 0	
21	
22	
2 3	
2 4	
2 5	

```
Page 127
     the question.
 1
 2.
           Α.
                 That could happen.
                 Okay. So it's -- I think, as you
 3
           0.
     said, certainly plausible that individuals who
 4
     end up overdosing on an opioid never intended
     to take one, right?
 6
 7
                 MR. LEDLIE: Object to the form of
     the question.
 8
 9
                 That could be the case.
                 All right. We've talked about the
10
           0.
1 1
     opioid epidemic and your understanding of it.
12
                 Do you believe that Akron faces a
13
    prescription opioid epidemic?
14
                 MR. LEDLIE: Object to the form of
15
     the question.
16
           Α.
                 T do.
17
                 And when did that prescription
    opioid epidemic begin, in your opinion?
18
19
                 I believe that it -- that it
           A .
20
    started in -- like I had mentioned before, in
    the late '90s when we started to see a
21
22
    significant number of -- of reports and other
23
    interactions that suggested that.
24
                 (Thereupon, Deposition Exhibit 6,
2.5
```

Veritext Legal Solutions

www.veritext.com

888-391-3376

Page 185

because they're computer-generated reports.

- Q. Do you recall discussing, with your leadership at the time, that you were seeing these increases?
- MR. LEDLIE: Object to the form of the question.
- A. I don't recall specifically. I do know that there was a change in -- in awareness about -- hadn't heard of OxyContin. Hear of OxyContin, and then start to see another report, another report, another report, and, you know, Percocet and some of the other prescription medications, then, that were frequently being reported as stolen or stolen, it stood out.
  - Q. Right. And I -- and I just want to understand. I know it stood out to you. Are you aware that it stood out to others as well?
  - A. Through -- yes. I mean, through casual conversations that I wouldn't be able to pinpoint, you know, "I spoke to Sergeant Jones," you know, "on this date about it."

    But, yes, there was a growing familiarity within the department that that was
- problematic.

2.

Page 186 Starting in the late 1990s? 1 0. 2 Α. I think so. 3 Okay. Have you ever sought a Ο. budget allowance specific to anything caused by 4 opioids? 5 6 Α. Can you restate that? 7 0. Sure. Have you ever -- have you ever asked for any kind of a specific budget 8 9 allowance related to opioids in any way? 10 MR. LEDLIE: Object to the form. 11 No, other than people resources, Α. 12 I've not had a financial request. 1.3 Q. You say "other than people 14 resources." Have you asked for specific people 15 resources related to opioids? 16 Α. Yes. 17 Tell me about that. Q. Α. 18 The first two -- this wasn't me asking at that point in time, but the -- the 19 20 first two detectives that were dedicated, they 21 were taking from our -- taken from our 22 narcotics or bid, in addition to our current --23 the staffing at that time for narcotics, two 24 positions for opioid death investigations. 2.5 Then there was another point that

Veritext Legal Solutions
www.veritext.com
888-391-3376